Myqorzo sales jump 427% despite competition; Cytokinetics shows balanced risk/reward with strong Q2 revenue.

Myqorzo sales surged 427.1% quarter-over-quarter to $25.3 million in Q2, outperforming Bristol Myers Squibb's Camzyos in treating symptomatic nonobstructive HCM, according to Phase 3 data. Cytokinetics reported a 47.8% revenue increase to $28.6 million and a better-than-expected non-GAAP EPS of -$1.5. However, safety concerns arose with 10.5% of patients experiencing reversible LVEF reductions on aficamten versus 0.8% on placebo. The current risk/reward profile for Cytokinetics appears balanced amid competitive and safety challenges.